124 0 0 0 OA ワクチンの医療経済評価
- 著者
- 赤沢 学
- 出版者
- 一般社団法人 日本臨床薬理学会
- 雑誌
- 臨床薬理 (ISSN:03881601)
- 巻号頁・発行日
- vol.41, no.5, pp.245-252, 2010 (Released:2010-11-25)
- 参考文献数
- 18
- 被引用文献数
- 2 1
A number of new vaccines for preventable diseases such as meningitis and cervical cancer are getting available for Japanese children. However, those vaccines are categorized as voluntary vaccination and their costs should be paid by recipients. Therefore, high cost is a barrier for access to the preventive care. In addition, subsidiary by local governments causes their regional disparities. On the other hand, the Advisory Committee on Immunization Practices (ACIP) in the United States recognizes importance of economic analyses in establishing policy for addition of new vaccines to routine immunization schedules. The ACIP publishes guidance for health economic studies to ensure that high quality economic data are presented in a standard format. In this study, a critical review of economic analyses for childhood vaccine programs in Japan was conducted. Six original studies that included varicella, mumps, Hib (haemophilus influenza type B), pneumococcal disease and human papillomavirus vaccines were identified by a systematic literature review. The results of all studies suggested that these new vaccines should be included to routine immunization schedules because expected benefits would outweigh additional costs of vaccines. However, according to the check lists recommended by ACIP guideline, these studies utilized various sources of cost information and calculated opportunity costs differently. Some studies did not consider discounting of future costs. Therefore, direct comparisons between studies were very difficult. Economic analyses to evaluate the priority of vaccine programs should follow a standard method to increase comparability and quality of studies.
言及状況
外部データベース (DOI)
Twitter (124 users, 136 posts, 77 favorites)
https://t.co/95UWvCAuXU
そういえば、今回のコロナワクチンで費用便益効果を出すとどうなるんだろうか。そもそもの疾病負担は機会損失がメインとなると思うが、疾病よりも政策による負担の方が桁違いに大きいのではないだろうか。
これが子宮頸がんワクチン HPVワクチン日本導入の根拠になった費用対効果の算出。
ワクチンの金額が36000円で計算されており(実際は3回で5万円)一生効果がある前提。
しかも、副反応の関しては全く算出されておらず、副反応によってかかる医療費や補償にも言及していない。
https://t.co/ukdVmlN8bp https://t.co/5AjdwgAtAV
2010年9月 ワクチンの医療経済評価
明治薬科大学 赤沢学https://t.co/YjTUJ2pgmv
最近、医薬品の医療経済評価で五十嵐中氏の名前をよく目にしますが、ワクチンの医療経済評価は国立病院機構三重病院の神谷斎氏もなさっていた。
神谷氏は23年2月に急逝
https://t.co/ikxdJJmFUu